Acurx Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

9 Months Ended

Sep. 30, 2024

NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of September 30, 2024 and December 31, 2023 were as follows:


	September 30, 2024		December 31, 2023
Accrued research and development	$	2,968,508	$	2,263,934
Accrued compensation expenses		247,210		716,307
Accrued professional fees		83,950		58,388
Other accounts payable and accrued expenses		19,097		3,809
Total	$	3,318,765	$	3,042,438